01/28/2025
Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?
Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?
A study found that “pacritinib may offer a unique survival advantage” for patients with myelofibrosis (MF) and thrombocytopenia who achieve any spleen volume reduction (SVR). The study was led by Helen Ajufo, MD, of Washington University School of Medicine in St. Louis, Missouri, and published i...
01/27/2025
We have started a new forum on our mobile app for hem/ons to ask Dr. Hagop Kantarjian your questions. Visit our sohoinsider.com page for directions on how to download the mobile app and ask your questions!
Get started👉https://sohoinsider.com/news/new-ask-dr-kantarjian-your-leukemia-questions/
01/23/2025
Dr. Garcia-Manero discusses mature data on luspatercept’s efficacy in MDS
Watch the video:
Dr. Garcia-Manero discusses mature data on luspatercept’s efficacy in MDS
Guillermo Garcia-Manero MD, of the University of Texas MD Anderson Cancer Center, discusses long-term data from the COMMANDS trial, highlighting the use of luspatercept (Reblozyl) as a first-line treatment for lower-risk myelodysplastic syndromes (MDS). After 1.5 years, one-third of patients maintai...
01/22/2025
We're proud to announce and welcome our newest SOHO Corporate Partner, Autolus! Learn more about Autolus at www.autolus.com
Learn more about SOHO Corporate Partnerships👉 http://soho.click/partner
01/14/2025
Subscribe to http://sohoinsider.com, the one and only official news source of the Society of Hematologic Oncology. (Please note that Blood Cancers Today is no longer affiliated with SOHO.)
01/09/2025
Presence of circulating lymphoma cells a significant adverse risk factor in DLBCL
Presence of circulating lymphoma cells a significant adverse risk factor in DLBCL
The largest study to date evaluating the impact of circulating lymphoma cells (CL) on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) found that presence of CL at diagnosis was associated with inferior response rates and survival compared to those without CL.....
01/08/2025
Are driving restrictions too stringent for patients being treated with ? This analysis takes a closer look. What do you think?
Researchers call for ‘evidence-based’ driving restrictions for patients treated with CAR-T therapy
Driving restrictions for blood cancer patients undergoing chimeric antigen receptor (CAR)-T cell therapy may need reconsideration, according to research presented by Rahul Banerjee, MD, FACP, of the University of Washington Fred Hutchinson Cancer Center, at the 66th ASH Annual Meeting and Exposition...
01/07/2025
Still deciding if is the right path for you? Join us at (soho.click/2025) to get inspired! Still don't believe us? Hear what past SOHO attendees have to say about the meeting's impact on their career:
Aspiring hem/onc fellows discuss myeloma research, SOHO Annual Meeting opportunities
Wajeeha Aiman, MD, and Muhammad Ashar Ali, MD, discuss the benefits of attending the SOHO Annual Meeting in Houston, Texas, for early-career healthcare professionals. Drs. Aiman and Ashar also discuss their SOHO poster presentation on multiple myeloma and measurable residual disease negativity.
01/03/2025
“This is about more than AML. It’s about creating a model for how we can use science, technology, and collaboration to revolutionize cancer care,” Harry Erba said in an interview with SOHO Insider on the MyeloMATCH initiative.
Read the story here:
NCI’s myeloMATCH precision medicine initiative pushes the envelope in myeloid leukemia care
A new National Cancer Institute (NCI) initiative seeks to redefine the standard for personalized cancer care in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Known as MyeloMATCH—(Myeloid Malignancies Molecular Analysis for Therapy Choice)—the ambitious program integrates molec...
01/01/2025
Zamto-cel shows promise in interim results from phase 2 pivotal study Miltenyi Biotec
Zamto-cel shows promise in interim results from phase 2 pivotal study
SOHO Insider spoke with Toon Overstijns, CEO of Miltenyi Biomedicine, and Dr. Anna Wijatyk, CMO (USA) of Miltenyi Biomedicine, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, California. In the video interview, Overstijns and discuss interim results....
12/27/2024
We are in the final days of #2024 and we are in a celebratory mood 🥳 . Hear from our current SOHO President all about what we have accomplished this past year!
SOHO president looks back on 2024
For SOHO, 2024 was a year of firsts and continued growth of the society worldwide. Current SOHO President Phillip Scheinberg, MD, PhD, chief of hematology at the Hospital A Beneficência Portuguesa de São Paulo in Brazil, looks back on the year and what is in store for 2025.
12/16/2024
We are so excited to announce the launch of our new digital and print publication SOHO Insider. We will be covering the latest news in . Check out what our EIC Sagar Lonial, MD, has to say in this video
Introducing SOHO Insider
Sagar Lonial, MD, of Emory University, introduces SOHO Insider the new digital and print publication from the Society of Hematologic Oncology (SOHO). As the editor-in-chief and a past SOHO president, Dr. Lonial shares insights into this exciting launch in a video filmed during the 66th American Soci...
12/09/2024
Stay tuned for our in roundtable!!
12/07/2024
We are ready for . Stop by our booth 35 in the nonprofit section to say hello and sign up for membership!
12/05/2024
We are here at ! Visit us at booth 35 in the nonprofit section to get one of these little guys when you sign up for free membership. Grand Hyatt Manchester San Diego amazing view!
11/22/2024
📢 starts in less than 30 minutes. There is still time to register at http://soho.click/ssaunq. SOHO members register for free. Registration includes 3 months of on-demand access!🥳